Navigation Links
A minute crustacean invades the red swamp crayfish
Date:9/11/2012

The small ostracod Ankylocythere sinuosa measures no more than half a millimetre in length and lives on other crayfish. And, Spanish scientists have discovered it for the first time in Europe. The finding suggests that it arrived along with the invader crayfish Procambarus clarkii some 30 years ago but it is still unknown whether it can invade other crustacean species or whether it benefits or damages the expansion of the already established red swamp crayfish.

The red swamp crayfish (Procambarus clarkii) originates from the USA and Mexico and has been present in the Iberian Peninsula since the 1970's. Its expansion is currently on the up. However, its 'invasion' is coupled with that of another species: the ostracod Ankylocythere sinuosa, which is also from North America and totally relies on the crayfish to survive. It has now been discovered in Europe but could have come at the same time as its host 30 years ago.

Published in the 'Hydrobiologia' journal, the study aimed to verify how the Ankylocythere sinuosa arrived on the European Continent. According to researchers, although it has taken more than three decades to discover, "it is certain that it arrived with Procambarus clarkii".

"Ankylocythere sinuosa is common and abundant wherever there is the red swamp crayfish in Europe", as explained to SINC by Francesc Mesquita Joanes, lead author of the study and researcher at the Department of Microbiology and Ecology of the University of Valencia.

This minute epibiont crustacean lives on top of its host meaning it cannot live without the crayfish. It lays its eggs on the crayfish and clings on while it develops. The majority of crayfish are infected and "adult specimens can have up to many hundreds of ostracods on them," reveals Mesquita.

Hundreds of tiny crabs on the back of a crayfish

Between 2003 and 2009, the team of researchers took 203 red swamp crayfish from 12 differ
'/>"/>

Contact: SINC Team
info@agenciasinc.es
FECYT - Spanish Foundation for Science and Technology
Source:Eurekalert  

Page: 1 2

Related biology news :

1. Killer silk: Making silk fibers that kill anthrax and other microbes in minutes
2. A step toward minute factories that produce medicine inside the body
3. 30 minutes of daily exercise does the trick
4. Unexpected crustacean diversity discovered in northern freshwater ecosystems
5. The raccoon spreads dangerous diseases as it invades Europe
6. Carp dominate crayfish in invasive species battleground
7. Crayfish species proves to be the ultimate survivor
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
A minute crustacean invades the red swamp crayfish
(Date:12/17/2014)... Dec. 15, 2014 Research and Markets ... of the "Samsung Galaxy S5 - Home ... to their offering. ... different sensing technology than the iPhone 5S, Samsung ... in its product. The Galaxy S5 ...
(Date:12/17/2014)... 2014 Research and Markets ( ... "Global Chemical Sensor Market 2015-2019" report ... http://photos.prnewswire.com/prnh/20130307/600769 One major trend upcoming ... medical sensors in biomedical applications. Chemical sensors help ... correct diagnosis during surgical procedures. The Global Chemical ...
(Date:12/11/2014)... Research and Markets , ... http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition of the ... to their offering. One major ... of multimodal biometric systems. Multimodal biometric systems utilize ... verification and identification purposes. This helps to reduce ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... to be particularly prone to global warming caused by ... greenhouse gases. Now, a University of Utah study finds ... north: the Arctic's well-known haze ?made of particulate pollution ... better able to trap heat. , The effect makes ...
... dioxide from fossil fuel burning are dramatically altering ... that secrete skeletal structures and support oceanic biodiversity. ... effects of increased atmospheric carbon dioxide on these ... research for determining the extent of the impacts. ...
... stem cells, prized for their astonishing ability to apparently transform ... identities in part by interacting with their surroundings - even ... dish, University of Florida scientists report. , Using an animal ... Brain Institute have begun to answer one of the most ...
Cached Biology News:Pollutant haze heats the Arctic 2Pollutant haze heats the Arctic 3Pollutant haze heats the Arctic 4Report warns about carbon dioxide threats to marine life 2Report warns about carbon dioxide threats to marine life 3Medium is the message for stem cells in search of identities 2Medium is the message for stem cells in search of identities 3
(Date:12/22/2014)... , Dec. 22, 2014   Synthetic ... developer of pathogen-specific therapies for serious infections ... the microbiome, today announced positive topline safety ... clinical trial of SYN-004, the Company,s investigational ... Clostridium difficile (C. difficile) infection, ...
(Date:12/22/2014)... Calif. , Dec. 22, 2014  ( www.competitivehealth.com ... CoPatient, an online medical bill review and advocacy service, ... in the FREE WellCard Savings discount health services marketplace. ... bill that was more than they expected to pay. ... reduce health care costs, WellCard Savings is pleased to ...
(Date:12/19/2014)... December 19, 2014 Bioject Medical ... and manufacturer of needle-free injection technology, today announced ... Immunomic Therapeutics, Inc. (“ITI”) for ITI to use ... its LAMP™ vaccine platform. , In the ... Worldwide license to the Biojector®-2000 that triggers based ...
(Date:12/19/2014)... PLEASANTON, Calif. , Dec. 19, 2014  Roche ... acquisition of Bina Technologies, Inc. (Bina), a privately ... California , USA. Bina provides a big ... next generation sequencing (NGS) data. Bina,s proprietary on-market ... translational and academic researchers to perform fast and ...
Breaking Biology Technology:Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3Roche acquires Bina Technologies and enters the genomic informatics market 2Roche acquires Bina Technologies and enters the genomic informatics market 3
... PALO ALTO, Calif., Feb. 20 CV Therapeutics, Inc. ... board of directors has thoroughly reviewed and rejected the ... acquire CV Therapeutics at a price of $16.00 per ... its independent financial and legal advisors, the CV Therapeutics ...
... Nyenrode Business,Universiteit has awarded a Honorary Doctoral degree ... microeconomics, competitive strategy and cluster,theory. Professor Porter is ... of strategy and the world,s most influential thought ... Professor Porter will receive,the Honorary Doctorate on Wednesday ...
... $0.90 to $1.10 for 2009 and $1.50 to $1.70 for 2010PITTSBURGH, ... announced its financial results for the three and twelve months ended ... to $1.10 for 2009 and $1.50 to $1.70 for 2010. , ... Adjusted diluted EPS of $0.26 and $0.80 ...
Cached Biology Technology:CV Therapeutics' Board of Directors Rejects Astellas Unsolicited Proposal 2CV Therapeutics' Board of Directors Rejects Astellas Unsolicited Proposal 3CV Therapeutics' Board of Directors Rejects Astellas Unsolicited Proposal 4Nyenrode Honorary Doctorate for Professor Michael E. Porter 2Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 2Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 3Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 4Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 5Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 6Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 7Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 8Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 9Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 10Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 11Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 12Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 13Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 14Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 15Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 16Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 17
... ImmEdge Pen, a hydrophobic barrier pen for ... for use with frozen or paraffin-embedded tissue ... Pen provides a heat-stable, water-repellent barrier that ... sections, prevents mixing of reagents when differentially ...
... Covance's BCIP/NBT Chromogen system ... Tetrazolium] chromogen in a single ... reacts in the presence of ... purple staining with minimal background ...
... CellBIND surface is produced by a patented ... surface giving more consistent, even cell attachment, ... cell attachment and growth uunder difficult conditions, ... CellBIND may provide a more ecominic alternative ...
SphingoStripsTM contain fifteen different biologically active, nitrocellulose-immobilized lipids at 100 pmol per spot, which can be assayed for protein binding and specificity using a simple blot ove...
Biology Products: